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hrombospondin-1 (TSP-1) contains three type 1 repeats
(TSRs), which mediate cell attachment, glycosamino-
glycan binding, inhibition of angiogenesis, activation
of TGF
 
 
 
, and inhibition of matrix metalloproteinases. The
crystal structure of the TSRs reported in this article reveals
a novel, antiparallel, three-stranded fold that consists of
alternating stacked layers of tryptophan and arginine residues
from respective strands, capped by disulﬁde bonds on each
T
 
end. The front face of the TSR contains a right-handed
spiral, positively charged groove that might be the “recog-
nition” face, mediating interactions with various ligands.
This is the ﬁrst high-resolution crystal structure of a TSR
domain that provides a prototypic architecture for structural
and functional exploration of the diverse members of the
TSR superfamily.
 
Introduction
 
The thrombospondins (TSPs)* are a family of five matricel-
lular glycoproteins that regulate extracellular matrix structure
and cellular phenotype (for reviews see Bornstein, 1995;
Chen et al., 2000). These modular proteins act by bringing
together cytokines, growth factors, other matrix components,
membrane receptors, and extracellular proteases. TSP-1, for
instance, regulates cell proliferation, migration, and apoptosis
in a variety of physiological and pathological settings, such
as wound healing, inflammation, angiogenesis, and neoplasia
(Chen et al., 2000). The inhibition of angiogenesis involves
the inhibition of endothelial cell migration and the induction
of endothelial cell apoptosis (Tolsma et al., 1993; Jimenez et
al., 2000). In addition, TSP-1 inhibits the mobilization of
VEGF from the extracellular matrix by matrix metallopro-
teinase 9 (Rodriguez-Manzaneque et al., 2001). TSP-1 can
also suppress the growth of TGF
 
 
 
-responsive tumor cells
through activation of this cytokine (Miao et al., 2001). The
420-kD TSP-1 molecule is trimeric and each protomer is
composed of multiple domains: NH
 
2
 
- and COOH-terminal
globular domains; a procollagen-like domain; and three
types of repeated sequence motifs, designated type 1, 2, and
3 repeats (Lawler and Hynes, 1986). The type 1 repeats
(designated TSP-1 domain in the pfam database or throm-
bospondin repeat [TSR] elsewhere) were initially identified
in human endothelial cell TSP-1 (Lawler and Hynes, 1986).
Database searches at that time revealed that a similar struc-
tural motif was present in the complement factors C8 and
C9 and in the circumsporozoite protein of the 
 
Plasmodium
falciparum
 
 parasite. Since then, the TSR domain has been
identified in multiple different protein families (for review
see Adams and Tucker, 2000). The human genome has 41
proteins that contain TSRs and the 
 
Caenorhabditis elegans
 
and 
 
Drosophila
 
 genomes have 27 and 14 proteins with
TSRs, respectively (Venter et al., 2001). The copy number
of the TSR in these proteins varies from 1 to 18. All of the
TSRs are in secreted proteins or in the extracellular portion
of transmembrane proteins. They appear to be involved in
cellular migration, communication, and tissue remodeling
in complex tissues. The TSR domain consists of 
 
 
 
60 amino
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acids, of which 12 are highly conserved. Most notably, the
NH
 
2
 
-terminal portion of the TSR contains two or three tryp-
tophan residues separated by two to four amino acids each
(Klar et al., 1992; Adams and Tucker, 2000; Kilpelainen et
al., 2000). The majority of TSRs have six cysteine residues;
however, those found in some complement factors and in the
malaria proteins contain fewer cysteines. In addition, two ar-
ginines and two glycines are also highly conserved.
The functions of the three TSRs that are present in
TSP-1 have been extensively studied. They reportedly
function as (a) attachment sites for many cell types, (b) in-
hibitors of angiogenesis, (c) protein binding sites, and (d)
glycosaminoglycan (GAG) binding sites (for review see
Chen et al., 2000). Synthetic peptides have been used to
identify amino acid residues within the TSRs of TSP-1
that are important for the anti-angiogenic activity. Tolsma
et al. (1993) found that peptides from the second and
third TSRs that included the CSVTCG sequence inhibit
angiogenesis. This sequence is reportedly involved in the
binding of TSP-1 to CD36, and CD36 on endothelial
cells reportedly mediates the anti-angiogenic effect of
TSP-1 (Dawson et al., 1997). However, two groups have
shown that synthetic peptides that flank either side of the
CSVTCG sequence, but do not include it, also inhibit
angiogenesis (Dawson et al., 1999; Iruela-Arispe et al.,
1999). One of these includes the W**W**W (the asterisk
indicates positions that are occupied by various amino
acids) sequence that has been proposed to be a GAG
binding site (Guo et al., 1992). The other sequence,
GVITRIR, contains the highly conserved arginine resi-
dues (Dawson et al., 1999).
A unique function has been mapped to the sequence be-
tween the first and second TSRs of TSP-1. This region
binds and activates TGF
 
 
 
 (for review see Murphy-Ullrich
and Poczatek, 2000). This activity is mediated by the tripep-
tide RFK of TSP-1 and is conserved in all TSP-1 sequences
determined to date. By contrast, this sequence is not found
in the TSRs of most other proteins, including the closely re-
lated TSP-2 protein. An RFK sequence is found in the sixth
TSR of F-spondin but it falls in a different location within
the sequence and, to date, it has not been shown to activate
TGF
 
 
 
 (Klar et al., 1992).
Taken together, the data indicate that the TSR-contain-
ing proteins participate in development, angiogenesis, tu-
mor progression, axon guidance, activation of TGF
 
 
 
, and
wound healing. Some of the amino acid sequences that
mediate TSR functions have been identified. However,
several nonoverlapping synthetic peptides have been re-
ported to have similar functions. To better understand the
biological function of the TSRs, we have determined the
three-dimensional structure of the TSRs of human TSP-1
by X-ray crystallography.
 
Table I. 
 
Data collection, structure determination, and refinement
Data set
Hg peak Hg inflection Hg remote Native
 
Data collection
Space group
 
C
 
2
 
C
 
2
Unit cell (Å, 
 
 
 
)a  
 
 
 
 67.94, b 
 
 
 
 83.97,
c 
 
 
 
 37.17, 
 
 
 
 
 
 
 
 108.37
a 
 
 
 
 67.63, b 
 
 
 
 84.41,
c 
 
 
 
 37.17, 
 
 
 
 
 
 
 
 108.67
X-ray source APS APS
Wavelength (Å) 1.00803 1.00808 1.05969 1.1000
Resolution (Å) 20 
 
 
 
 2.50 20 
 
 
 
 2.50 20 
 
 
 
 2.50 20 
 
 
 
 1.90
Observations 65741 65699 66576 162978
(unique) (6903)
 
a
 
(6872)
 
a
 
(6996)
 
a
 
(15485)
I/
 
 
 
 overall 12.5 (3.5)
 
b
 
11.7 (4.1)
 
b
 
12.8 (2.6)
 
b
 
14.6 (3.8)
 
b
 
Completeness (%) 99.9 (99.9)
 
b
 
99.9 (99.9)
 
b
 
99.6 (97.1)
 
b
 
99.8 (99.7)
 
b
 
R
 
merge
 
 (%) 10.5 (31.0)
 
b
 
11.4 (24.0)
 
b
 
10.5 (39.5)
 
b
 
7.5 (46.9)
 
b
 
Structure determination
Resolution (Å) 10 
 
 
 
 3.0
Figure of merit 0.535
Phasing power (1.73/1.09)
 
c
 
(2.11/1.56)
 
c
 
R
 
Cullis
 
 (dispersive) 0.95 0.92
R
 
Cullis
 
 (isomorphous) (0.71/0.78)
 
c
 
0.64/0.65)
 
c
 
Structure refinement
Resolution (Å) 20 
 
 
 
 1.90
Number of work/test reflections 13590/1533
Nonhydrogen protein/carbohydrate/solvent atoms 844/20/154
R
 
Work
 
/R
 
Free
 
 (%) 23.8/28.2
Bond length (Å)/angle (
 
 
 
) rms deviation from ideal geometry 0.008/1.631
Ramachandran statistics (%)
(Favorable/additional/generous/forbidden) 83.9/16.1/0/0
Protein atoms average B value (Å
 
2
 
), mainchain/sidechain 39.70/41.42
 
a
 
Including Bijvoet pairs.
 
b
 
(Last resolution bin).
 
c
 
(Acentric/centric). 
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Results
 
Crystal structure determination of the h3TSR
 
A soluble recombinant protein containing all three TSRs of
human TSP-1 (designated h3TSR) was expressed in 
 
Dro-
sophila
 
 S2 cells. We have previously shown that this protein,
h3TSR, is active in that it activates TGF
 
 
 
 and inhibits en-
dothelial cell migration, angiogenesis, and tumor growth
(Miao et al., 2001). The h3TSR contains 186 amino acid
residues, including Asp358–Ile530 of human TSP-1, six
vector-derived amino acids (RSPWPG) at the NH
 
2
 
 termi-
nus, and two vector-derived amino acids (TG) followed by a
His tag at the COOH terminus. Crystals were obtained that
diffracted to 1.9 Å resolution, and the structure was solved
by the multiple-wavelength anomalous diffraction (MAD)
method (Hendrickson, 1991) using a Hg-derivatized crystal
(Table I). Only residues from TSR2 and TSR3 are seen in
the electron density maps. SDS-PAGE run on crystal sam-
ples revealed a single band with a molecular mass of around
17 kD, corresponding to a two TSR domain protein (un-
published data). Although the three TSRs in the intact TSP-1
protein are resistant to protease digestion, apparently the
high concentration of h3TSR in the crystallization droplet
exposes the highly basic sequence of KRFK between TSR1
and TSR2 to a trypsin-like protease for degradation. The fi-
nal model hence just includes the second and third TSRs ar-
ranged in tandem with a total of 117 residues. For the fol-
lowing discussion, we will refer to this model as hTSR[2,3].
 
The overall hTSR[2,3] structure
 
Fig. 1 A is a ribbon diagram of the molecular structure of
hTSR[2,3]. Each TSR folds into a long, thin, spiraling, anti-
parallel, three-stranded domain with dimensions of 
 
 
 
15
 
 
 
20
 
 
 
55 Å. The core of each domain is a novel eight-layered
structure that will be described in detail below. The tilt and
twist angles between TSR2 and TSR3 are 40
 
 
 
 and 180
 
 
 
, re-
spectively. The 180
 
 
 
 twist places the TSR2 and TSR3 do-
mains facing in opposite directions. DALI search with the
TSR domain (using the website http://www2.ebi.ac.uk/dali/)
failed to identify any homologous structures in the database.
The TSR2 and TSR3 domains are the products of exons 9
and 10 of the human TSP-1 gene, respectively. The excep-
tion is Ile473, which is encoded by exon 9 but does not be-
long to TSR2. Rather, Ile473 forms two main chain hydro-
gen bonds to Gln507, joining the top portions of the TSR3
domain. The three residues at the COOH terminus of exon
10 are not visible in the electron density map of the current
crystal structure. Pro472 appears to be a linker between the
TSR2 and TSR3 domains. Immediately before Pro472 is the
disulfide bridge of Cys471–Cys433, which stabilizes the con-
formation of the bottom portion of the TSR2 domain. The
residue Pro472 (the linker between TSR2 and TSR3) and
its spatially neighboring residues Ala470, Cys471, Ile473,
Phe508, and Gly509 create a hydrophobic interface between
the two domains. These data suggest that there is a relatively
rigid linkage between the TSR2 and TSR3 domains. Based
on the amino acid sequence alignment shown in Fig. 1 B, the
TSR1 domain should have a very similar fold as that of the
TSR2 and TSR3 domains. A distinct feature of the linkage
between the TSR1 and TSR2 domains is that there is a five-
residue linker (D411KRFK), as opposed to just the one resi-
due that is between TSR2 and TSR3. Presumably, the link-
age between TSR1 and TSR2 is very flexible. The structures
of TSR2 and TSR3 are so similar that the rmsd value for the
superposition of TSR2 and TSR3 is only 0.62 Å (two loops
are excluded). Therefore, unless otherwise indicated, only
TSR2 is used for the discussion below.
Two types of glycosylation have been identified biochemi-
cally in the TSRs (Hofsteenge et al., 2001). Hofsteenge et al.
(2001) have demonstrated that a fucose is O-linked to the
threonine in the CSVTCG sequence motif on each TSR.
Our electron density maps have clearly shown that one fu-
cose moiety each can be built onto the TSR2 and TSR3 do-
mains and no electron density beyond this sugar unit is visi-
ble. The modeled glycan is located on the AB loop at the
bottom of each domain (Fig. 1 A). Another potential glyco-
sylation is the C-mannosylation of the first tryptophan of
the W**W motif (Hofsteenge et al., 1999, 2001). In platelet
TSP-1, for instance, Trp367, Trp420, Trp423, and Trp480
are C-mannosylated (Hofsteenge et al., 2001). The S2 ex-
pression system used in this work, however, does not allow
Figure 1. The structure of hTSR[2,3]. (A) A stereo view of the 
ribbon diagram of hTSR[2,3]. The disulfide bonds (in yellow) and 
O-linked fucose moieties (in gray) at Thr432 and Thr489 are drawn 
in ball and stick representation. The small and large jar handle 
motifs in each TSR domain are highlighted in dark red and purple, 
respectively. (B) The sequence alignment of hTSR domains. The   
strands are underlined for strands B and C, whereas the bulged 
strand A is marked by a dashed line. The disulfide bonds are marked 
in dark yellow lines connecting paired cysteines. The tryptophans 
that form the W layers are shown in green and the amino acids that 
form the R layers are shown in blue. The pairing between amino 
acids from the B and C strands that form the R layers is marked by 
blue lines. The serine residues of the A strand that contribute to 
hydrogen bonds to the backbone of the B strand (see Fig. 4) are in 
red. The linker residues between TSR domains are in purple. Fig. 1 
A was prepared using the program MOLSCRIPT (Kraulis, 1991). 
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for this posttranslational glycosylation (Hofsteenge et al.,
2001). There is indeed no electron density to be seen for any
C-manosylation in our calculated maps. However, the side
chains of all three tryptophans on each TSR are so oriented
that the C
 
 
 
1 atoms are exposed, ready for accommodation
of mannoses (Hartmann and Hofsteenge, 2000) (Fig. 2).
The function of this glycosylation is not well studied.
 
The CWR-layered core structure of the TSR fold
 
Small domains like the TSR (
 
 
 
100 amino acid residues) very
often have special folds that lack regular secondary structure
and are maintained by the rich presence of disulfide bonds or
metal ions (Richardson, 1981). The exceptions are some re-
cently identified small modules, such as SH3 (Pawson, 1995)
and WW (Macias et al., 1996) domains, that are present in a
number of signal transduction proteins and that do have reg-
ular secondary structures as basic folding elements. The TSR
domain described in this article, however, represents a novel
fold, for which the interdigitating side chain stacking of cys-
teine, tryptophan, and arginine in layers (the CWR layer)
from three strands comprises the core of the structure (Fig.
2). Only the B and C strands form limited regular 
 
 
 
 struc-
tures (Fig. 1). By contrast, the A strand assumes a unique rip-
pled conformation (Fig. 1 A; Fig. 2) and has a conserved se-
quence motif of W**W**W (Fig. 1 B). As shown in Fig. 2 A,
the side chains of the three tryptophans (Trp420, Trp423,
and Trp426 of TSR2) make up three tryptophan layers (the
W layers) that play a central role in the fold. Sandwiched be-
tween each of the two adjacent W layers is one guanidinium
group of an arginine from strand B. A comparison of the
amino acid sequences of the TSRs from various proteins re-
veals that the sequence R*R*R is commonly found in strand
Figure 2. CWR-layered core structure of the TSR 
domain. (A) A stereoview of C, W, and R layers in 
TSR2 of TSP-1. Displayed residues that are directly 
involved in forming the layered structure are 
drawn in ball and stick representation with salt 
bridges, and hydrogen bonds drawn as dashed 
lines. The big jar handle motif, which is associated 
with the first W layer is highlighted in pink. (B) A 
schematic drawing of the CWR-layered structure 
with each layer and layer-forming residue(s) 
labeled. The residue Glu459 that is marked with 
an asterisk forms a hydrogen bond between its 
main chain carbonyl group and the side chain 
of Arg442 in the R1 layer. The three antiparallel 
strands are drawn in lines schematically with 
arrowheads indicating their polarities. The three 
bulges associated with the rippled strand A and 
the big jar handle are also shown. Fig. 2 A was pre-
pared using the program MOLSCRIPT (Kraulis, 
1991).
Figure 3. Multiple sequence alignment of TSRs. 
The alignment, in particular, compares the amino 
acid sequence of layer-forming residues in two 
major groups of TSRs as discussed in the text. The 
prototypical disulfide bond patterns of groups 1 
and 2 are drawn schematically in the left margin 
with disulfide bonds as yellow lines. Group 1 is in 
the top panel, and group 2 is in the middle panel. 
For group 1, two hydrogen bonds between the 
small jar handle and NH2 terminus are drawn as 
red lines. In the sequences, cysteines that form 
disulfide bond are also yellow, whereas those that 
are unpaired or involved in “extra” disulfide bonds 
are magenta. Tryptophans or tryptophan substituents 
in W layers are in green, and arginines or arginine 
substituents as well as their paired residues in R 
layers in cyan. In the bottom panel, the sequences 
of TSR-like domains from midkine and HB-GAM 
are aligned. 
Crystal structure of the TSR |
 
 Tan et al. 377
 
B (Fig. 3). These arginines comprise the R layers. The alter-
nate stacking of the planar cationic guanidinium groups of
the arginines and the aromatic side chains of the tryptophans
forms multiple cation-
 
 
 
 interactions (Flocco and Mowbray,
1994; Gallivan and Dougherty, 1999), which may provide
vital stabilization energy for TSR folding. The spacings be-
tween the R and W layers are observed to be around 4.6 Å
throughout TSR2 and TSR3. A similar structural element is
found in the class I cytokine receptor family. The so-called
“WSXWS box” is observed in this family, but its function is
controversial (Somers et al., 1994). In the human growth
hormone receptor, for instance, the stacked tryptophans and
arginines come from four different strands on the same face
of a membrane proximate Ig-like domain. This face is not
involved in hormone binding, nor receptor dimerization
(de Vos et al., 1992). The erythropoietin receptor has the
WSXWS sequence motif in a 
 
 
 
 bulge, and the pyrrole rings
of two Trps sandwich a guanidinum group of an Arg from a
neighboring 
 
 
 
 strand (Livnah et al., 1996). The uniqueness
of the TSR domain is that, to our knowledge, it is the first ex-
ample in which the alternately stacked W and R layers
capped by C layers constitute the major structural feature of
the domain. In the TSRs of other proteins, a glutamine or
lysine sometimes replaces the first arginine in the sequence
(the R3 layer in Fig. 3). In TSP-1, TSR1 and TSR3 have a
glutamine in the R3 layer, whereas TSR2 has an isoleucine.
The amino group from a lysine and the amide group from a
glutamine can also participate in cation-
 
 
 
 interaction with a
tryptophan residue (Flocco and Mowbray, 1994; Gallivan
and Dougherty, 1999).
The arginines in the R layers also always interact with a res-
idue from the C strand laterally, either in a salt bridge like the
Arg440–Glu462 pair, or in a hydrogen bond to the carbonyl
group like the Arg442–Glu459 pair. In TSR2, Ile438 in the
R3 layer makes hydrophobic contacts with Lys464 of the C
strand between the aliphatic portions of their side chains.
The sequence alignment shown in Fig. 3 demonstrates that
the residues in the R layers from the B strand and their inter-
acting partners in the C strand frequently have large side
chains. This suggests that the contacts between hydrophobic
portions of the paired side chains may also play a role in sta-
bilizing the TSR domain. In TSR3 of TSP-1, Gln495 in the
R3 layer and Gln521 from strand C form a typical hydrogen
bond between the NE2 atom and OE1 atom of their respec-
tive amide groups. Again, we see a spectrum of variation in
the R3 layer among different TSR domains.
The six alternated W and R layers are capped by disulfide
bonds at the top and bottom, hence the two C layers. These
are Cys444–Cys456 and Cys429–Cys466 in TSR2 (Fig. 2),
Cys501–Cys513 and Cys486–Cys523 in TSR3, and their
conserved counterparts in other TSRs (Fig. 3). Fig. 2 B de-
picts the eight CWR–layered fold of the TSR2 domain in a
schematic manner. Within the eight layers (in the order of
C1, W1, R1, W2, R2, W3, R3, and C2 from top to bottom),
all of the side chains that form the CWR-layered structure are
in a planar and parallel conformation. Even the side chain of
Ile438 in the R3 layer of TSR2 assumes the best possible ori-
entation for stacking. Due to the inherent strand twist, the
whole CWR-layered structure is in a right-handed spiral con-
formation, reminiscent of a DNA structure.
The rippled A strand with its multiple bulges is another
interesting feature of the eight-layered TSR domain. As
mentioned previously, the A strand is not a regular 
 
 
 
 strand.
It nevertheless has a unique hydrogen bonding network to
the B strand. Fig. 4 shows how a serine after each of the
tryptophans in the W layers and after the COOH-terminal
Cys429 on the A strand forms two hydrogen bonds to the
backbone of the B strand: one via its hydroxyl side chain and
the other with its amide group. The formation of side chain
to main chain hydrogen bonds between the two antiparallel
strands creates even larger bulges in comparison to a well-
defined wide bulge (Richardson, 1981). A threonine or a
glycine sometimes replaces the serine in these positions in
other TSRs (Fig. 3). The former can act like a serine, and
Figure 4. Rippled A strand and jar handle motifs. 
(A) A stereoview of the bulged strand A, the jar 
handle motifs, and their associated hydrogen bond 
networks. Displayed side chains of staggering 
tryptophans, serines, and other relevant residues 
are drawn in ball and stick representation. For the 
residues marked with asterisk, only main chain 
atoms that are involved in hydrogen bonds are 
shown. The big and small jar handles are high-
lighted in pink and dark red, respectively. (B) A 
schematic drawing of the hydrogen bond network 
between the antiparallel bulged strand A and the 
regular   strand B. The serine residues that are 
involved in the formation of side chain to main 
chain hydrogen bonds between the two strands 
are shaded in yellow. Fig. 4 A was prepared using 
the program MOLSCRIPT (Kraulis, 1991). 
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the latter allows a sharp turn. They all favor the bulged con-
formation for the A strand. This hydrogen bonding network
between the A and B strands, the regular 
 
 
 
 structure of the B
and C strands, the disulfide bonds, and the side chain stack-
ing of the CWR-layered structure ensure a stable folding
unit for this small domain.
 
The “jar handle” structures
 
The CWR-layered structure is the core of TSR domain. At
the bottom of both the TSR2 and TSR3 domains, a cysteine
on the AB loop forms the third disulfide bond with a cys-
teine in the COOH terminus of strand C (Fig. 1 A; Fig. 4
A). This disulfide bond consolidates the bottom of the do-
mains. At the top of the domains, there is a relatively long
BC loop that tends to be enriched in proline, glycine, or
charged amino acids in the TSRs of various proteins. In the
TSR structure of TSP-1, the loop features a regular 
 
 
 
 turn
in the middle and two “jar handle”–like structures at the be-
ginning (the dark red–colored smaller one in Fig. 1 A and
Fig. 4 A) and the end (the purple-colored larger one in Fig. 1
A and Fig. 4 A). The small jar handle is at the beginning of
the BC loop and above the C1 layer (the Cys444–Cys456
pair in TSR2; Fig. 4 A). It appears somewhat like a conven-
tional 
 
 
 
 turn composed of four residues (Asn445–Ser448),
but the characteristic hydrogen bond within the turn is miss-
ing. Instead, the amide group of the second residue (Ser446)
and the carbonyl group of the third residue (Pro447) turn to
form hydrogen bonds to the main chain of the NH
 
2
 
 termi-
nus of the A strand (Fig. 4 A). This unique local structure
brings the beginning of the A strand closer to the BC loop,
while the nearby disulfide bond in the C1 layer cross-links
the B and C strands. Together, the interactions stabilize the
top of the domain. The third residue is a cis-proline in both
TSR2 and TSR3, which may favor the formation of a jar
handle. In TSR1 and the TSRs of some other proteins, this
proline is absent (Fig. 1 B; Fig. 3). It is difficult to convinc-
ingly predict if this small jar handle exists in these proteins.
The unusual handle structure acts just like the serine hydro-
gen bonding network to integrate the A strand into the do-
main (Fig. 4 A). As discussed later, a disulfide bond may
serve this function in the TSRs of some other proteins.
The large handle (purple in Fig. 1 A and Fig. 4 A) is at the
end of the BC loop, and immediately below the C1 layer. It
consists of five residues (Cys456–Ala460). The interesting
features of this handle are that the third position is a con-
served Gly458, and the carbonyl group of the second resi-
due, Glu457, forms a hydrogen bond to the NH1 atom of
the tryptophan in the W1 layer (Fig. 4 A). This allows this
tryptophan’s bulky side chain to be accommodated within
the handle. By contrast, the tryptophans in the W2 and W3
layers have their polar NH1 atoms exposed and available for
potential ligand binding.
 
A positively charged groove on the “front” face of the 
TSR: the proposed “recognition” face
 
The above-mentioned exposed tryptophans from the W lay-
ers along with the exposed arginines from the R layers define
the “front” face of the domain. This is best seen in Fig. 2 A,
where the three strands run along the “back,” providing a
framework to support a continuous positively charged front
face containing side chains from the W and R layers. Other
residues that are located at the edge of the A and C strands
also help to create a groove-like structure within this posi-
tively charged region. Fig. 5 A is a molecular surface repre-
sentation of TSR2 with a few residues labeled on the surface.
This figure clearly depicts this DNA-like right-handed spiral
groove. We propose that this is likely to be the “recognition
face” of the domain. The molecular orientation in Fig. 1 A
sets the TSR2 domain’s recognition face away from the
reader, whereas the TSR3 domain’s recognition face is to-
ward the reader.
Having the structure of TSP-1 TSRs at hand enables us to
interpret some functional data that are largely based on pep-
tide studies. In general, a short linear peptide cannot easily
mimic its counterpart in a folded TSR domain. Neverthe-
less, some peptide investigations are still suggestive, as dis-
cussed below.
 
Discussion
 
GAG binding properties of TSRs
 
GAGs and proteoglycans constitute one major component
of extracellular matrix. GAGs are long, unbranched polysac-
charide molecules composed of repeating disaccharide units.
One of the disaccharides is always a uronic acid, whereas the
second one is an 
 
N
 
-acetylglucosamine or 
 
N
 
-acetylgalac-
tosamine, which are usually sulfated, rendering the molecule
very negatively charged. The ability to bind GAGs is impor-
tant to the function of many extracellular and membrane
proteins. TSRs have been reported to mediate GAG binding
in several proteins. Crystal structures of heparin–protein
complexes indicate that a cluster of positively charged resi-
Figure 5. Electrostatic potential surface 
representation of TSRs. (A) The front and 
back faces of TSP-1 TSR2 with charged 
residues labeled. The two orientations are 
related by a rotation of 180 . (B) The front 
face of a modeled C-mannosylated TSP-1 
TSR2 with two mannoses attached to 
W420 and W423 as labeled. (C) The 
front face of a homologous model of 
ADAMTS-4 TSR. (D) The front face of a 
homologous model of F-spondin TSR6. 
This figure was prepared using the pro-
gram GRASP (Nicholls et al., 1991).Crystal structure of the TSR | Tan et al. 379
dues on a protein’s surface can interact with the negatively
charged carboxylate and sulfate groups of heparin (Pellegrini
et al., 2000; Lietha et al., 2001). Heparin molecules are in a
right-handed helical conformation, and the disaccharide re-
peat of heparin spans  9 Å (Mulloy et al., 1993). The dis-
tance between the W1 layer and R3 layer in the TSR is close
to 20 Å. It is conceivable that two spiral disaccharide units
may fit well into the right-handed groove in the recognition
face of the TSR. The C-mannosylation on some tryp-
tophans (Hofsteenge et al., 2001) of TSP-1 TSRs does not
significantly change their surface electrostatic potential, but
creates protrusions along the edge of the grooves (Fig. 5 B).
The mannose groups may help to define the groove in the
recognition face. Because the separation of two arginines in
the groove is also  9 Å, the speculation might be that the
negatively charged groups of GAGs can form electrostatic
interactions with these arginines. TSRs of TSP-1 have a rela-
tively low affinity for heparin that may not be detectable at
physiological salt concentrations (Panetti et al., 1999), sug-
gesting that residues other than the tryptophans and argi-
nines, in particular residues from the C strand, may contrib-
ute significantly to GAG binding.
The protein ADAMTS-4 or aggrecanase-1 is a newly
identified cartilage-degrading enzyme. It contains one TSR,
which is highly homologous to the TSRs of TSP-1. The
strong binding of the TSR of ADAMTS-4 to the GAG side
chains of aggrecan (the major sulfate proteoglycan in carti-
lage) appears to be necessary for the enzymatic cleavage of
aggrecan that occurs during disease-related cartilage de-
struction (Tortorella et al., 2000). It has been reported that
synthetic peptides that include sequences found in the A
and C strands of the TSR of ADAMTS-4 have weak affini-
ties for aggrecan. The C strand of the ADAMTS-4 TSR
contains more arginine residues than the TSRs of TSP-1
(Fig. 3). Fig. 5 C shows the surface representation of the
ADAMTS-4 TSR domain, which has been modeled based
on the TSR structure of TSP-1 reported here. This figure
demonstrates that positive charges cover nearly the entire
front face of this TSR domain due to the extra positively
charged residues from the C strand. This model may ex-
plain the high binding affinity of ADAMTS-4 for the GAG
chains of aggrecan.
F-spondin is a matrix-associated protein that is expressed
in the floor plate and involved in patterning the axonal tra-
jectory of commissural and motor neurons. F-spondin has
multiple TSRs in its COOH terminus as well as reelin and
mindin homologous regions in the NH2 terminus (Klar et
al., 1992; Tzarfaty-Majar et al., 2001). The interaction of
the F-spondin TSRs with extracellular matrix and neuronal
growth cones has been reported to involve binding to GAGs
(Klar et al., 1992; Tzarfaty-Majar et al., 2001). This binding
is mediated by the fifth and sixth TSRs, whereas the first
four TSRs are not involved. Comparing the sequence of the
TSRs of F-spondin with those of TSP-1 reveals that the fifth
and sixth TSRs of F-spondin have more basic residues on
the C strand and BC loop (Fig. 3). These basic residues con-
tribute positive charges to the front face of these TSRs as
they do in the ADAMTS-4 TSR. For example, the residues
of Glu457 and Glu459 (Fig. 5 A) in TSR2 of TSP-1 are
substituted by Lys794 and Lys796 in TSR6 of F-spondin,
respectively (Fig. 3). The only two acidic residues (an aspar-
tic and a glutamic acid) on the C strand of TSR6 in F-spon-
din point away from the front surface. The front face of
TSR6 is therefore dominated by a cluster of positively
charged residues, as shown in Fig. 5 D.
The interaction of TSRs with GAGs is also involved in
cellular invasion by apicomplexia. This process is central to
the life cycle of P. falciparum and to the etiology of malaria.
Host cell invasion involves the binding of circumsporozoite
protein and thrombospondin-related anonymous protein
(TRAP) on the parasite surface to GAGs on the surface of
salivary glands in the mosquito and liver hepatocytes in the
vertebrate host (Matuschewski et al., 2002). Mutations in
the TSR sequence of TRAP result in a decrease in the ability
of the parasite to invade salivary glands and liver cells (Wen-
gelnik et al., 1999; Matuschewski et al., 2002). Mutation of
the tryptophan in the W3 layer to alanine or substitution of
the positively charged amino acids in and around the R lay-
ers with alanine residues decreased sporozoite infectivity of
the salivary gland (Matuschewski et al., 2002). Because these
residues are integral components of the CWR-layered struc-
ture, our data suggest that these mutations would disrupt
the overall folding of the TSR and the formation of the rec-
ognition face.
Taken together, these data suggest that positive charges
across the front face of a TSR are essential for high-affinity
binding to GAGs in many important biological processes.
More basic residues in the C strand and elsewhere around
the front face probably contribute to stronger binding.
The binding of TSP-1 to CD36
TSP-1 is one of several naturally occurring inhibitors of an-
giogenesis. The inhibition of angiogenesis by TSP-1 is re-
portedly due in part to CD36-mediated inhibition of endo-
thelial cell migration and induction of apoptosis (Dawson
et al., 1997; Jimenez et al., 2000). Peptides having se-
quences from strand A and the sequence of GVITRIR from
strand B of the second TSR have been shown to have the
inhibitory activities (Tolsma et al., 1993; Dawson et al.,
1999; Iruela-Arispe et al., 1999; Jimenez et al., 2000). The
major portions of these peptides can now be mapped on the
front face of the TSR structure presented here. On the
other hand, the region between amino acids 90 and 120 of
CD36 has been implicated in TSP-1 binding (Leung et al.,
1992; Pearce et al., 1995). Secondary structure predictions
(using the website http://www.embl-heidelberg.de/predict-
protein/predictprotein.html) suggest that the sequence
T(103)QDAEDN of CD36 falls into a negatively charged
loop. This sequence is conserved in human and mouse
CD36. We hypothesize that this negatively charged loop of
CD36 may interact with the positively charged groove of
the TSR’s front face. The CSVTCG sequence has also been
implicated in the interaction of TSP-1 with CD36. Upon
careful examination of the folded TSR, one sees that the
two cysteines in the CSVTCG sequence are involved in two
separate disulfide bonds and that the threonine is O-glyco-
sylated (Hofsteenge et al., 2001). Thus, the activities of
synthetic peptides may not correlate with the function of
the CSVTCG sequence in the context of the three-dimen-
sional structure of the TSR.380 The Journal of Cell Biology | Volume 159, Number 2, 2002
Disulfide bond pattern and TSR grouping
A close scrutiny of the TSRs in the database reveals consid-
erable variability (Fig. 3). Based on the disulfide bond pat-
terns and multiple sequence alignment algorithms, we ten-
tatively divide TSRs into two major groups represented by
the TSRs of TSP-1 (group 1) and F-spondin (group 2).
The major difference is the disulfide bond at the top of
TSR’s layered structure (the C1 layer), as illustrated at the
left margin of Fig. 3.
The TSRs of TSP-1 are the prototype of group 1. Within
this group (Fig. 3, top), the C1 layer at the top of the do-
main is formed by cysteines from the end of the B strand
and the beginning of the C strand. In some of these TSRs,
such as TSRs found in TSP-2, BAI-1, -2, and -3, ADAMTS
family members, properdin, and others, there is a third di-
sulfide bond at the bottom of the domain that helps to con-
solidate the bottom of the domain as described before.
There are also TSRs found in the COOH terminus of the
complement factors C6, C7, C8 , C8 , and C9, in which
this third disulfide bond is absent. Instead, there appears an
unpaired cysteine residue between the first and second tryp-
tophans on the A strand (Fig. 3).
The structure of group 2 can be predicted for the TSRs of
F-spondin. In these TSRs, the cysteines that form the C1
layer are predicted to be from the A and C strands, rather
than from the B and C strands (Fig. 3, bottom). This disul-
fide bond pattern is found in midkine (Iwasaki et al., 1997).
Thus, the beginning of the A strand is linked to the top por-
tion of the domain through this disulfide bond. Note that in
group 1, it is a jar handle–like element that integrates the A
strand into the top of the domain (represented by two hy-
drogen bonds in red in Fig. 3, top). Like those TSRs in
TSP-1, the TSRs of F-spondin also have a third disulfide
bond at the bottom of the domain. TSRs of M-spondin,
mindin-1 and -2, the NH2-terminal of complement factors,
and TRAP/CTRP (circumsporozoite protein from P. fal-
ciparum) may fall into the same category. In the TRAP TSR
and CTRP TSR1, 2, 3, 5, 6, and 7, the first tryptophan on
the A strand is absent, presumably resulting in a seven-lay-
ered TSR core structure. An extra disulfide bond may exist
in a few TSRs, like TSR2 of properdin, in which the NH2
terminus of the A strand is probably linked to the beginning
of the C strand (see two cysteines in red for TSR2 of proper-
din in Fig. 3).
Midkine and HB-GAM have two TSR-like domains
(Iwasaki et al., 1997; Kilpelainen et al., 2000). Sequence
alignment demonstrates their large deviation from TSRs of
other proteins (Fig. 3, bottom). The NMR structure of mid-
kine’s TSR-like domains (Iwasaki et al., 1997) showed that
although their overall topology is reminiscent of that of
TSP-1’s TSRs reported here, they depart substantially in the
CWR-layered structure of a TSR domain. Not only are the
layers significantly fewer, but they can hardly be structurally
compared with that found in TSP-1’s TSRs. Fig. 6 is the su-
perposition of the NH2-terminal TSR-like domain of mid-
kine from the NMR structure onto TSR2 of the TSP-1. The
layered positioning of tryptophan and arginine residues to
form multiple cation-  interactions is a key feature of the
TSP-1 TSRs. This does not seem to exist in midkine where
there is only one potential cation-  interaction. A DALI
search with TSP-1’s TSR domain did not detect similarity
to the structure of midkine, indicating that the structures are
distinct.
The disulfide bond–based grouping might provide a
framework to aid functional studies. For example, some pro-
teins in groups 1 and 2 seem to differ in their effects on an-
giogenesis. The TSRs that are present in TSP-1, TSP2, BAI-1,
and ADAMTS-1 in group 1 have been shown to inhibit an-
giogenesis (Nishiomori et al., 1997; Vázquez et al., 1999).
By contrast, some of the proteins in group 2, including two
members of the CCN family and HB-GAM, reportedly
stimulate angiogenesis (for review see Lau and Lam, 1999;
Papadimitriou et al., 2001).
Materials and methods
Protein production, crystallization, and X-ray data collection
A recombinant version of all three TSRs of human TSP-1, designated
h3TSR, was prepared by PCR using the full-length cDNA of human TSP-1,
as described previously (Miao et al., 2001). For crystallization, the purified
protein was dialyzed against 20 mM Na3PO4 (pH 7.8) containing 500 mM
NaCl, and was reapplied to a column of ProBond resin. The protein eluted
with 500 mM imidazole was dialyzed against 20 mM Na3PO4 (pH 7.0) and
500 mM NaCl, and 1% sucrose was added before storage at  80 C.
Single crystals of h3TSR were grown from a crystallization buffer con-
taining 0.5 M sodium potassium tartrate and 0.1 M sodium acetate at pH
5.5 using the vapor diffusion hanging drop method. For the data collection
at cryogenic temperature, the crystals were treated with a cryoprotectant
solution (25% glycerol, 0.5 M sodium potassium tartrate, 0.1 M sodium
acetate, pH 5.5), and then frozen and stored in liquid nitrogen. Mercury
Figure 6. A stereo view of a structure superposition of TSP-1 
TSR2 (in light blue) and the NH2-terminal domain of midkine 
(in brown). Residues mostly from the   strand regions of the two 
structures, including W426–S430, D435–R440, and R461–K468 from 
TSP-1 TSR2 and W20–T24, V32–G37, and T43–V50 from the NH2 
terminus of midkine (Protein Data Bank code, 1mkn), were used for 
the least squares structure alignment. Residues with displayed side 
chains in ball and stick representation are those highlighted in the 
TSP-1 TSR2 and NH2-terminal midkine sequences aligned in Fig. 3. 
The NH2 and COOH termini of the two structures are labeled. This 
figure was prepared using the program MOLSCRIPT (Kraulis, 1991).Crystal structure of the TSR | Tan et al. 381
derivatives were prepared by soaking the crystals in the same cryopro-
tectant solution containing 1 mM ethylmercury chloride for 4 h. X-ray dif-
fraction data were collected from prefrozen crystals at APS SBC 19ID at a
temperature of 100 K. A native crystal diffracted to a resolution of 1.9 Å,
with one molecule in one asymmetric unit. A MAD dataset of the mercury
derivative was obtained to a resolution of 2.1 Å. All the raw data were in-
dexed and reduced with HKL2000 (Table I).
Structure determination and refinement
Using programs in the CCP4 suite (CCP4, 1994), we located one major Hg
binding site in one asymmetric unit in both isomorphous and anomalous
difference Patterson maps. Considering possible nonisomorphism between
the native and Hg derivative crystal, the MAD data alone from Hg deriva-
tive were actually used for heavy atom parameter refinement and phasing
with the high-energy dataset as reference. After the refinement and initial
phasing at 3 Å resolution with the program MLPHARE in the CCP4 suite,
an additional minor Hg binding site was identified and two sites were re-
fined together. Phase extension was performed subsequently using the na-
tive data to 2.5 Å by solvent flattening and histogram matching with DM
(Cowtan, 1994). An improved Fourier map was obtained and used for ini-
tial model building with the program O (Jones et al., 1991). After each step
of model building, the combined phases from experimental and calculated
from the partial model were used to perform density modification. The
model building cycle was repeated until  90% of the residues from TSR2
and TSR3 were built into the model.
The native dataset was eventually used for the completion of model
building and refinement. The final model was refined at 1.9 Å resolution to
an Rfree factor of 28.2% and Rwork of 23.8% (Table I) using the Xplor
(Brunger, 1992). At a 1.5 sigma contour level in 2Fo-Fc map, there was
continuous density for the main chain backbone except for part of the gly-
cine-rich AB loop and the COOH terminus of TSR3. The final model con-
tains 113 residues (from Gln416 to Cys528) with two O-linked fucoses as-
sociated with residues Thr432 and Thr489. There was no indication on the
electron density maps for the existence of the first domain as mentioned
before. The current model also includes a total of 154 water molecules.
The coordinates have been deposited in the Protein Data Bank under the
accession code 1LSL.
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